Immediate-Release Cannabinoid Composition for Low-Dose Uniformity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of pharmaceutical formulations for N-(2-(tert-butyl)-1-((4,4-difluorocyclohexyl)methyl)-1H-benzimidazol-5-yl)ethanesulfonamide (Compound I) is hindered by the need for very low therapeutic doses, poor flowability and cohesion of the active substance, instability in solution, and challenges in achieving content uniformity and stability during manufacturing.
Innovation Solution
The use of a non-aqueous solvent, specifically polyethylene glycol, in combination with Compound I to create a semi-solid pharmaceutical composition that ensures uniform distribution, stability, and rapid release of the active substance, with at least 75% release within 45 minutes in an in vitro dissolution test.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If very low therapeutic doses of Compound I are used, then the desired therapeutic effect is achieved, but content uniformity and distribution uniformity deteriorate
Solution Approach 1:
The patent changes the physical state parameter of Compound I from solid to liquid by converting it to an amorphous form through co-evaporation with a carrier substance. This parameter change enables the compound to be uniformly distributed at very low doses (50-200 μg) throughout the pharmaceutical formulation, achieving both low dose therapy and content uniformity.
Solution Approach 2:
The patent creates a composite material system consisting of Compound I dispersed in an amorphous carrier substance (such as hydroxypropyl cellulose, gelatin, or sucrose). This composite approach allows the active ingredient to be uniformly distributed at trace levels while maintaining stability and achieving the required content uniformity for low-dose formulations.
2Ease of operation
If Compound I is used in solution form, then dissolution and absorption are facilitated, but chemical stability deteriorates due to degradation on exposure to light
Solution Approach 1:
The patent utilizes phase transition by converting Compound I from crystalline solid to amorphous liquid state through co-evaporation. This amorphous state provides enhanced dissolution characteristics similar to solutions while maintaining chemical stability by avoiding aqueous environments that promote degradation. The amorphous formulation dissolves rapidly in gastrointestinal fluids without requiring pre-dissolution in unstable aqueous solutions.
Solution Approach 2:
The patent introduces an amorphous carrier substance as an intermediary between the solid Compound I and the aqueous gastrointestinal environment. The carrier substance (hydroxypropyl cellulose, gelatin, or sucrose) forms an amorphous matrix that protects Compound I from direct exposure to water and light during storage, yet allows rapid dissolution and release of the active ingredient when contacted with gastrointestinal fluids.
3Ease of manufacture
If Compound I is poorly flowing and cohesive, then handling during manufacturing becomes difficult, but content uniformity cannot be achieved
Solution Approach 1:
The patent changes the physical state parameter of Compound I from solid to amorphous form, which fundamentally alters its flow and handling characteristics. The amorphous form eliminates intermolecular crystalline forces that cause poor flowability and cohesion, resulting in a material that flows freely and can be uniformly mixed and distributed throughout the pharmaceutical formulation at very low doses.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to pharmaceutical compositions comprising Compound I, or a pharmaceutically acceptable salt thereof, as the active substance. The pharmaceutical compositions are suitable for use in immediate release pharmaceutical formulations. The pharmaceutical formulations are suitable for use in the treatment of medical conditions in which treatment with agonists of CB1/CB2 receptors are beneficial.